CN101193861A - 具有抗肿瘤活性的吲哚衍生物 - Google Patents

具有抗肿瘤活性的吲哚衍生物 Download PDF

Info

Publication number
CN101193861A
CN101193861A CNA2006800205522A CN200680020552A CN101193861A CN 101193861 A CN101193861 A CN 101193861A CN A2006800205522 A CNA2006800205522 A CN A2006800205522A CN 200680020552 A CN200680020552 A CN 200680020552A CN 101193861 A CN101193861 A CN 101193861A
Authority
CN
China
Prior art keywords
compound
indol
pair
arom
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800205522A
Other languages
English (en)
Chinese (zh)
Inventor
C·皮萨诺
G·巴蒂斯图齐
M·迪马尔佐
G·詹尼尼
M·马尔齐
L·韦希
F·祖尼诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101193861A publication Critical patent/CN101193861A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800205522A 2005-06-10 2006-05-31 具有抗肿瘤活性的吲哚衍生物 Pending CN101193861A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05012562 2005-06-10
EP05012562.4 2005-06-10

Publications (1)

Publication Number Publication Date
CN101193861A true CN101193861A (zh) 2008-06-04

Family

ID=35062959

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800205522A Pending CN101193861A (zh) 2005-06-10 2006-05-31 具有抗肿瘤活性的吲哚衍生物

Country Status (13)

Country Link
US (1) US8053460B2 (https=)
EP (1) EP1891007A1 (https=)
JP (1) JP2008542428A (https=)
KR (1) KR20080029967A (https=)
CN (1) CN101193861A (https=)
AR (1) AR053891A1 (https=)
AU (1) AU2006256771A1 (https=)
BR (1) BRPI0612542A2 (https=)
CA (1) CA2607337A1 (https=)
EA (1) EA013542B1 (https=)
MX (1) MX2007015274A (https=)
TW (1) TW200716545A (https=)
WO (1) WO2006131484A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105367479A (zh) * 2015-11-16 2016-03-02 青岛大学 一种组蛋白去乙酰酶抑制剂2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基-n-(2-(羟氨基)-2-酮乙基)乙酰胺及其制备方法和应用
CN109928909A (zh) * 2019-04-02 2019-06-25 南华大学 具有抗抑郁活性化合物及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105669540A (zh) * 2009-01-28 2016-06-15 卡鲁斯治疗有限公司 Scriptaid电子等排体及其在治疗中的用途
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
JP6329958B2 (ja) * 2012-11-07 2018-05-23 カルス セラピューティクス リミテッド 新規ヒストンデアセチラーゼインヒビターおよび治療におけるその使用
NZ714283A (en) 2013-05-10 2020-04-24 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
CN120136763B (zh) * 2025-03-13 2025-10-10 遵义医科大学 一种c-3苄基化吲哚类化合物、制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887348A1 (en) 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
IT1317925B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Bis-eterocicli ad attivita' antitumorale e chemosensibilizzante.
EP1438044A1 (en) 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105367479A (zh) * 2015-11-16 2016-03-02 青岛大学 一种组蛋白去乙酰酶抑制剂2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基-n-(2-(羟氨基)-2-酮乙基)乙酰胺及其制备方法和应用
CN109928909A (zh) * 2019-04-02 2019-06-25 南华大学 具有抗抑郁活性化合物及其制备方法

Also Published As

Publication number Publication date
EA200702672A1 (ru) 2008-04-28
US8053460B2 (en) 2011-11-08
MX2007015274A (es) 2008-02-22
JP2008542428A (ja) 2008-11-27
AR053891A1 (es) 2007-05-23
AU2006256771A1 (en) 2006-12-14
EA013542B1 (ru) 2010-06-30
KR20080029967A (ko) 2008-04-03
WO2006131484A1 (en) 2006-12-14
EP1891007A1 (en) 2008-02-27
TW200716545A (en) 2007-05-01
BRPI0612542A2 (pt) 2010-11-23
CA2607337A1 (en) 2006-12-14
US20080207729A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
NO324939B1 (no) Akridinderivater, anvendelse derav, fremgangsmate for fremstilling derav samt medikament inneholdende minst ett akridinderivat
EP3749640B1 (en) Inhibitors of the wnt/beta-catenin pathway
CN102153564A (zh) 含氮原子的青蒿素二聚体、其制备方法及用途
CN101193861A (zh) 具有抗肿瘤活性的吲哚衍生物
CN1378447A (zh) 穿透细胞膜的靛类双吲哚衍生物的用途
CN112940050B (zh) 二茂铁衍生物及其制备方法和用途
CN102786509A (zh) 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途
WO2003018557A1 (fr) Hydrazinopeptoides et leurs utilisations dans le traitement des cancers
US8530517B2 (en) Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
CN105131082A (zh) 环肽类化合物及其应用
CN1781932A (zh) 阿霉素的衍生物及其制备方法和用途
CN1108297C (zh) 维甲酰香豆素类化合物及其制备方法和含该化合物的药物组合物
Zhou et al. Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability
US9499552B2 (en) Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof
HK1117829A (en) Indole derivatives having antitumor activity
CN101735113B (zh) 一类尿素衍生物及其制法与用途
CN1931840A (zh) 一类dna靶分子及其诱导细胞凋亡和抗肿瘤的应用
JP2008545772A (ja) 抗腫瘍薬として有用なケイ皮酸、フェニルプロピオル酸およびフェニルプロピオン酸誘導体
CN1409709A (zh) 用于抑制细胞增殖的取代的二吲哚基马来酰亚胺
AU2015316886B2 (en) 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer
Cheptea et al. New derivatives of 5‐nitro‐indazole with potential antitumor activity
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
Lu Synthesis of a Novel Benzosuberene Analogue as an Anti-Cancer Agent.
HK1058201B (en) Novel indole derivatives and their use as medicaments
CN1390846A (zh) 具有抗病毒、抗癌活性的氨基糖肽类新化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117829

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080604

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117829

Country of ref document: HK